Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics-Reference-Cited by-同舟云学术

Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics

Published:2020-11 Issue:5 Volume:78 Page:671-679
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Nguyen Bastien^ORCID,Mota Jose Mauricio^ORCID,Nandakumar Subhiksha^ORCID,Stopsack Konrad H.^ORCID,Weg Emily^ORCID,Rathkopf Dana,Morris Michael J.,Scher Howard I.,Kantoff Philip W.,Gopalan Anuradha,Zamarin Dmitriy^ORCID,Solit David B.,Schultz Nikolaus,Abida Wassim

Funder

U.S. Department of Defense

National Cancer Institute

Prostate Cancer Foundation

Publisher

Elsevier BV

Subject

Urology

Reference26 articles.

1. Integrated genomic analyses of ovarian carcinoma;Bell;Nature,2011

2. The \tancer;Abeshouse;Cell,2015

3. Integrative clinical genomics of advanced prostate cancer;Robinson;Cell,2015

4. The long tail of oncogenic drivers in prostate cancer;Armenia;Nat Genet,2018

5. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex;Ekumi;Nucleic Acids Res,2015

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer de prostate métastatique résistant à la castration et inhibiteurs de PARP : de la génomique tumorale aux nouvelles associations thérapeutiques;Bulletin du Cancer;2024-09

2. Biomarkers of prostate bladder and testicular cancers: current use in anatomic pathology and future directions;Surgical and Experimental Pathology;2024-08-20

3. Tracking down metabolic vulnerabilities in CDK12‐mutant prostate cancer;Clinical and Translational Discovery;2024-07-19

4. Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies;2024-07-19

5. Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer;2024-07-12